Heterocyclic modulators of lipid synthesis

A compound and cycloalkyl technology, applied in the field of heterocyclic regulators of lipid synthesis, can solve problems such as anemia, weakened nutrient absorption, impaired immune function, destruction, etc., and achieve anti-viral and anti-cancer therapy, improved anti-cancer Effects of virus and anticancer activity

Active Publication Date: 2015-07-22
GANNEX PHARM CO LTD
View PDF21 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Both radiation-based and cytotoxic-based therapies cause damage to rapidly dividing hematopoietic and intestinal epithelial cells, resulting in impaired immune function, anemia, and reduced nutrient absorption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic modulators of lipid synthesis
  • Heterocyclic modulators of lipid synthesis
  • Heterocyclic modulators of lipid synthesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[2528] Example 1-FASN inhibition by compounds of the present disclosure

[2529] Determination of FASN biochemical activity: FASN enzyme was isolated from SKBr3 cells. SKBr3 is a human breast cancer cell line with high FASN expression levels. It is expected that FASN contains approximately 25% cytosolic protein in this cell line. SKBr3 cells were homogenized in a Dounce homogenizer and then centrifuged at 4°C for 15 minutes to remove particulate matter. The supernatant was then analyzed for protein content, diluted to an appropriate concentration and used to measure FASN activity. The presence of FASN was confirmed by immunoblotting analysis. A similar method for isolating FASN from SKBr3 cells is described in Teresa, P. et al. (Clin. Cancer Res. 2009; 15(24), 7608-7615).

[2530] The FASN activity of SKBr3 cell extracts was determined by measuring the amount of thiol-containing coenzyme A (CoA) released during NADPH oxidation or during the fatty acid synthase reaction. The d...

Embodiment 2

[2531] Example 2-Antiviral activity

[2532] Use the HCV 1b replication system to evaluate the antiviral activity of the structure (I-Z):

[2533]

[2534] The replicon was constructed using the ET (luc-ubi-neo / ET) cell line, which is an HCV replicon with a stable luciferase (Luc) reporter and Three cell cultures were adapted to mutant Huh7 human liver cancer cell lines (Pietschmann et al. (2002) J. Virol. 76: 4008-4021). The HCV replicon antiviral evaluation analysis investigated the effect of the compound at six half-log concentrations. Human interferon alpha-2b was included in each operation as a positive control compound. The near-confluent culture of the ET line was plated out in a 96-well plate dedicated to the analysis of cell number (cytotoxicity) or antiviral activity, and the drug was added to the appropriate well the next day. When the cells are still near confluence after 72 hours, the cells are processed. Determine EC 50 (The replicon was inhibited by 50% and 90% ...

Embodiment 3

[2537] Example 3-FASN inhibition is related to HCV inhibition

[2538] The HCV replicon system was used to measure the antiviral activity of 15 compounds of the present disclosure (the numbers correlate with the compounds in Table 1). According to published methods (Lohmann et al., (1999) Science 285(5424): 110-113; Lohmann et al., (2001) J. Virol 75(3): 1437-1449 and Qi et al., (2009) Antiviral Res. 81(2):166-173), using Huh7 to establish a replicon cell line 1b (HCV 1b / Luc-Neo replicon (1b Con1 integrated with firefly genes)) by G418 selection. Use synthetic gene fragments to assemble the replicon. GT1b has PV-EKT and has 3 adaptive mutations E1202G (NS3), T1280I (NS3), K1846T (NS4B) and the backbone is Con1. The medium is:

[2539] a) DMEM supplemented with 10% FBS, G418 (250μg / ml), streptomycin (100μg / ml) / penicillin (100U / ml), L-glutamine (100×), NEAA (100×)

[2540] b) The culture medium is prepared as follows:

[2541] i) 500ml DMEM medium (Gibco, catalog number 11960-077) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

Compounds that are modulators of fatty acid synthesis are provided. The compounds are useful in the treatment of disorders characterized by dysfunctional fatty acid synthase by modulating fatty acid synthase function and / or fatty acid synthase pathway. Methods are provided for treating such disorders, including viral infections, such as hepatitis C infection, cancer, and metabolic disorders.

Description

[0001] Related application [0002] This application requires U.S. application No. 61 / 450,561 filed on March 8, 2011, U.S. application No. 61 / 508,611 filed on July 16, 2011, and U.S. application 61 / filed on January 11, 2012. 585,642 rights, each of which is incorporated herein by reference in its entirety for all purposes. Invention field [0003] The present disclosure generally relates to heterocyclic modulators of lipid synthesis and methods of use thereof. The lipid synthesis heterocyclic modulators of the present disclosure can be used to treat disorders characterized by fatty acid synthase dysfunction in individuals by modulating the fatty acid synthase pathway and / or fatty acid synthase function. Background of the invention [0004] Viral diseases are a major health problem that threatens most human groups. Some of the characteristics related to viral infections that health care professionals are concerned about include its highly infectious characteristics (such as HIV, S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/12C07D405/10C07D413/14A61K31/454A61P35/00A61P31/12
CPCC07D401/12C07D471/04C07D487/04C07D401/14C07D405/14C07D413/14C07D401/06C07D401/10C07D405/10C07D405/12C07D413/10C07D491/048C07D491/052C07D491/10A61K38/212A61K31/4525A61K31/7056A61K45/06A61K31/454C07D401/04C07D405/04C07D491/107C07D513/04A61P1/00A61P1/02A61P1/16A61P11/00A61P13/08A61P15/00A61P25/00A61P27/16A61P3/00A61P31/00A61P31/10A61P31/12A61P31/14A61P31/20A61P31/22A61P35/00A61P35/02A61P3/06A61P43/00A61P5/14A61P3/10Y02A50/30A61K2300/00A61K31/4545A61K31/496A61K31/5377A61K31/55A61K31/437
Inventor 约翰·D·欧斯罗勃罗伯特·S·麦克道尔拉塞尔·约翰逊杨汉飚马克·伊万奇科克里斯蒂安那·A·泽哈利亚蔡海英莉莉·W·胡
Owner GANNEX PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap